CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells
Authors Jiang S, Wang X, Zhang Z, Sun L, Pu Y, Yao H, Li J, Liu Y, Zhang Y, Zhang W
Received 21 June 2016
Accepted for publication 18 August 2016
Published 2 November 2016 Volume 2016:11 Pages 5505—5518
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Linlin Sun
Shuang Jiang,1,2,* Xiaobo Wang,2,* Zhiran Zhang,2 Lan Sun,3 Yunzhu Pu,3 Hongjuan Yao,3 Jingcao Li,3 Yan Liu,3 Yingge Zhang,3 Weijing Zhang1,4
1Department of Lymphoma, Affiliated Hospital of the Military Medical Academy of Sciences, Beijing, 2Department of Pharmacy, 210th Hospital of the People’s Liberation Army, Dalian, 3Key Laboratory of Nanopharmacology and Nanotoxicology, Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, 4Department of Lymphoma, Beijing Shijitan Hospital of Capital Medical University, Beijing, People’s Republic of China
*These authors contributed equally to this work
Abstract: A monoclonal antibody targeted nanoscale drug delivery system (NDDS) for chemotherapy was evaluated in CD20-positive Raji cells in vitro. Nanoparticles were formed by the assembly of an amphiphilic polymer consisting of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxypolyethyleneglycol-2000 (DSPE-PEG2000). Active carbon nanoparticles (ACNP) were conjugated to the chemotherapeutic agent, doxorubicin (DOX), and the nanoliposome carrier, DSPE-PEG2000 and DSPE-PEG2000-NH2 conjugated to the human anti-CD20 monoclonal antibody that targets B-lymphocytes. This monoclonal antibody targeted nanoparticle delivery system for chemotherapy formed the active NDDS complex, ACNP-DOX-DSPE-PEG2000-anti-CD20. This active NDDS was spherical in morphology and had good dispersion in the culture medium. When compared with the effects on CD20-negative YTS cells derived from natural killer/T-cell lymphoma, the active NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20, demonstrated DOX delivery to CD20-positive Raji cells derived from Burkitt’s lymphoma (B cell lymphoma), resulting in increased cell killing in vitro. The intracellular targeting efficiency of the ACNP-DOX-DSPE-PEG2000-anti-CD20 complex was assessed by confocal laser microscopy and flow cytometry. The findings of this in vitro study have shown that the DSPE-PEG2000 polymeric liposome is an effective nanocarrier of both a monoclonal antibody and a chemotherapy agent and can be used to target chemotherapy to specific cells, in this case to CD20-positive B-cells. Future developments in this form of targeted therapy will depend on the development of monoclonal antibodies that are specific for malignant cells, including antibodies that can distinguish between lymphoma cells and normal lymphocyte subsets.
Keywords: CD20, active carbon nanoparticles, doxorubicin, nanoscale drug delivery, targeted therapy, DSPE-NH2-anti-CD20 conjugate
Non-Hodgkin’s lymphoma (NHL) is currently classified into high- and low-grade, B- and T-cell lymphomas and accounts for at least 90% of the cases of lymphoma, with Hodgkin’s lymphoma and other forms of lymphoma representing the remaining 10% of cases. B-cell NHL is the most common type of NHL, accounting for 85% of cases in People’s Republic of China.1 Patients with high-grade, B-cell NHL may require treatment with high-dose chemotherapy and immunotherapy using monoclonal antibodies.2 New treatments for high-grade B-cell NHL now include liposomal doxorubicin (DOX),3 the anti-CD20 monoclonal antibody Rituximab,4 the CD20 monoclonal antibody-conjugated isotope Zevalin,5 and proteasome inhibitors including bortezomib,6 which have improved the treatment of B-cell NHL. However, statistics show that the 5-year survival rate of high-grade B-cell NHL, including diffuse large cell B-cell lymphoma, is <50%.7 Because these current forms of treatment options may have limited efficacy when used separately, it is possible that synergistic therapeutic effects will be obtained using the combination of chemotherapeutic and immunotherapeutic agents when they are delivered simultaneously to treat malignant lymphoma. Also, because systemic chemotherapy is toxic to normally proliferating cell populations, there is a need to develop more specific tumor-targeting drugs to reduce treatment toxicities.
In targeting therapy, nanoparticles have unique advantages.8–12 The enhanced permeability and retention effect is the theoretical foundation of tissue targeting of nanoparticle delivery systems. Nanoscale drug delivery systems (NDDS) have shown physical, chemical, pharmacokinetic, and pharmacodynamics properties, which give them advantages when compared with conventional pharmaceutical preparations in the treatment of malignant tumors.13–15
Active carbon nanoparticles (ACNP) have been used as an indicator of lymphatic circulation16 and act as a sustained-release drug delivery carrier17,18 with low toxicity19,20 and a large drug loading (DL) capacity due to their graphene composition.21–23 ACNP have been shown to have a constant rate of drug delivery and long drug half-life with effective drug delivery to their target tissues, especially to lymphatic tissues.24–29 However, ACNP preparations have poor water solubility and dispersion. Carbon nanoparticles can be coated with functional phospholipids, including amphiphilic polymers consisting of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxypolyethylene glycol-2000 (DSPE-PEG2000), which improve the water solubility and stability of ACNP preparations. When components of DSPE-PEG2000 are replaced with DSPE-PEG2000-NH2, the –NH2 molecule will react with the –COOH molecule of antibodies to form DSPE-PEG-antibody conjugates.
Studies of protein/antibody and therapeutic agents cotransported by nanoparticles for targeting therapy have made a lot of progress.30–32 The antibodies that are used in NDDS can target antigens on the cell surface, the effects of ACNP that carry chemotherapeutic drugs, and the stability of nanoparticles modified with PEG2000 have the potential to be used as targeted therapy in vivo to achieve active and passive targeted lysis of tumor cells.
Because of these recent developments, the present study was undertaken using a monoclonal antibody targeted NDDS for chemotherapy in CD20-positive Raji cells in vitro. Nanoparticles were formed by the assembly of DSPE-PEG2000, with ACNP conjugated to the chemotherapeutic agent, DOX, and the nanoliposome carrier DSPE-PEG2000, and DSPE-PEG2000-NH2 conjugated to the human anti-CD20 monoclonal antibody that targets B-lymphocytes.
Materials and methods
ACNP (200 nm) were obtained from the Shanghai Hainuo Carbon Industry Co., (Shanghai, People’s Republic of China). The zeta potential of the ACNP (−49.8±1.50 mV) was detected with the Zetasize 3000 HS Laser Particle Size and Zeta Potential Analyzer (Malvern Instruments Ltd, Malvern, UK). The content of C was 97.58%, H was 0.05%, and O was 0.12%. Recombinant anti-CD20 chimeric monoclonal antibody (anti-CD20 antibody) and fluorescein isothiocyanate (FITC)-conjugated recombinant anti-CD20 chimeric monoclonal antibody (FITC-CD20 antibody) were provided by Shanghai Zhangjiang Biotechnology Co. Ltd (Shanghai, People’s Republic of China). DSPE-PEG2000 and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-amino-polyethylene glycol-2000 (DSPE-PEG2000-NH2) were purchased from the Shanghai Advanced Vehicle Technology Co. Ltd (Shanghai, People’s Republic of China). DOX hydrochloride (DOX·HCl) was purchased from Kainuochuntian Biotech (Beijing, People’s Republic of China). 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC·HCl) and N-hydroxysuccinimide (NHS) were purchased from Shanghai Medpep Co. Ltd (Shanghai, People’s Republic of China). Hoechst 33258 and 4′,6-diamidino-2-phenylindole nuclear staining solution were purchased from Beyotime Biotechnology (Shanghai, People’s Republic of China). The cell proliferation kit (MTT) and colorimetric cell viability assay kits were provided by Beijing CellChip Biotechnology Co., Ltd (Beijing, People’s Republic of China).
Construction and preparation of ACNP as drug carrier systems
Purification of ACNPs
Initially, 3 g of commercially available ACNPs (200 nm) were suspended in sterile distilled water (2 L), and the mixed ACNP suspension was precipitated at room temperature for 72 hours. The supernatant was collected and filtered successively with 0.25 and 0.1 μm microporous membranes, and ACNPs with a particle size of 100–150 nm were obtained. The purified ACNPs were lyophilized and stored at −20°C.
Preparation of ACNP-DOX
Purified ACNPs 100 mg were activated at 100°C for 2 hours and suspended in triple-distilled water. Then, 50 mg of DOX were added to the ACNP suspension using magnetic stirring for 30 minutes at room temperature in phosphate-buffered saline (PBS), pH 7.4. The solution was bathed in ice in an intermittent ultrasound field for 4 hours. The suspension was centrifuged at 16,000 rpm for 20 minutes. The ACNP-DOX precipitates were collected, resuspended, and centrifuged to remove unbound DOX. The supernatants were collected, and the DOX concentration was measured in an ultraviolet (UV) spectrometer. The DL coefficient and the encapsulation efficiency were calculated from the DOX concentration in the supernatant, using formulae (1) and (2), as given below.33 The ACNP-DOX was freeze-dried and stored at −20°C until required for further use.
Preparation of ACNP and ACNP-DOX coated with functionalized phospholipid
DSPE-PEG2000 and DSPE-PEG2000-NH2 (5:1, w/w) were mixed and dissolved in organic solvent (chloroform: methanol =4:1 v/v). The prepared ACNP-DOX/ACNP was added to the DSPE-PEG2000 organic solution and mixed ultrasonically (DSPE-PEG2000:DSPE-PEG2000-NH2: ACNP/ACNP-DOX =5:1:2). The organic solvent was evaporated using a rotary evaporator at 30°C. Following evaporation, the walls of the container were lined by the phospholipid complex. The ACNP-DOX-DSPE-PEG2000-NH2 was redispersed in PBS using ultrasonic mixing. The final concentration of ACNP-DOX in ACNP-DOX-DSPE-PEG2000-NH2 was 1 mg/mL, and the corresponding final concentration of DOX was 250 μg/mL.
Preparation of the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 (Figure 1)
For the covalent attachment of anti-CD20 antibodies onto the nanoparticle surface, EDC and NHS reagents were used. EDC·HCl (1 mg/mL) was added to 5 mL of the prepared ACNP-DOX-DSPE-PEG2000-NH2 or ACNP-DSPE-PEG2000-NH2 and 200 μL of anti-CD20 antibody (10 mg/mL). Following gentle mixing for 30 minutes at room temperature, the pH of the reaction solution was adjusted to 8.5 with NaOH solution. Next, 1.7 mg of NHS was added to the reaction solution and the solution was stirred for 2 hours at room temperature. The solution was dialyzed for 12 hours in PBS (pH 7.4) using a 100 kDa dialysis bag for 12 hours, to obtain the final product, which was the monoclonal antibody targeted NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20.
Determination of the DOX release rate from the DDS
For each complex, 5 mg of ACNP-DOX, ACNP-DOX-DSPE PEG2000 and ACNP-DOX-DSPE-PEG2000-anti-CD20 were each dispersed in 2 mL of PBS at pH 7.4 and pH 5.5 and transferred to disposable 3,500 kDa molecular weight cut-off dialysis bags, which were sealed and then immersed in 20 mL of release medium with vortex mixing at 100 rpm at 37°C. A 1 mL volume of release medium was taken at predetermined time intervals, followed by immediately supplementing an equal volume of fresh medium. The concentration of released DOX in the medium was determined by UV–visible spectroscopy, and the amount of released DOX (W) was calculated using the formula:
W = VC
where V was the volume of medium and C was the DOX concentration in the medium.
The cumulative release rate (RR, %) was calculated using the formula:
where Wi is the measured amount of DOX in the release medium at the given time point, and Wt is the total DOX amount in the equal volume of ACNP suspensions before dialysis. Each experiment was repeated in triplicate.34
Characterization of the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20
The particle size, polydispersity index, and zeta potential values were measured using Nano Series Zen 4003 Zetasizer (Malvern Instruments Ltd).33 The suspension stability of ACNP, ACNP-DOX, ACNP-DSPE-PEG2000, ACNP-DOX-DSPE-PEG2000 and the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 in PBS (10 mM, pH 7.4) were observed by mixing 1 mg of corresponding preparation in 2 mL of PBS, followed by sonication for 30 minutes at room temperature.
The stability of the compound was evaluated after 1 month. The size and morphology of the ACNP-DOX, ACNP-DSPE-PEG2000, ACNP-DOX-DSPE-PEG2000 and the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 were evaluated using transmission electron microscopy (TEM) (Hitachi H7650, Hitachi Ltd., Tokyo, Japan). Each 0.1 mg/mL of sample was resuspended in water and mixed by sonication for 30 seconds. One drop of this suspension was placed on a carbon-coated copper TEM grid (200 mesh, Sangerbio, People’s Republic of China) and allowed to dry at room temperature. The samples were imaged at 80 kV with TEM. The absorption spectra were recorded in the range 200–900 nm using a UV–visible absorption spectrometer. Fluorescence spectra were recorded by a FluoroLog steady-state spectrofluorometer (excitation at 488 nm) with the same DOX concentration.34
Raji cells, derived from human Burkitt’s lymphoma, were obtained from the Shanghai Institute of Cell Biology, Shanghai, People’s Republic of China, and were cultured in Roswell Park Memorial Institute 1640 medium (Gibco, Billings, MT, USA) supplemented with 10% heat-inactivated fetal bovine serum (Gibco) and antibiotics (penicillin 100 U/mL, and streptomycin 100 μg/mL).35 Cells were cultured in 5% CO2 at 37°C. Cells were passaged every 2 days, and cells in logarithmic growth phase were used for experiments. The YTS cell line, derived from human natural killer/T-cell lymphoma (kindly donated by Scott Kaufmann, Mayo Clinic, Rochester, MN, USA), was cultured in the same way as for the Raji cells.
CD20-positive expression rate of Raji and YTS cells
Following the addition of 50 μL of 1.55 mg/mL FITC-anti-CD20 to 100 μL of Raji or YTS cell suspension, the unstained cell suspension and FITC-anti-CD20-labeled cell suspension were incubated simultaneously in the dark for 2 hours at 37°C. The incubated cell suspensions were centrifuged at 900 rpm for 3 minutes, the supernatant was removed, the cells were washed twice with PBS, and the number of CD20-positive cells was measured using flow cytometry.
Atomic force microscopy
Preparation of the coverslips coated with L-poly-lysine
The coverslips were washed with 75% ethanol and soaked in 1 mg/mL L-poly-lysine PBS solution for 2 hours at room temperature. The coverslips were gently washed five times with triple-distilled water to remove excess L-poly-lysine and then dried. The 100 μL of cell suspension was placed on prepared L-poly-lysine-coated coverslips for 2 minutes, followed by removal of the excess PBS, and the cells were fixed with 100 μL of paraformaldehyde (4%) for 15 minutes, washed five times with PBS, and three times with triple-distilled water, and air-dried.
Observation of cells with atomic force microscopy
The cells were observed using high-resolution, tapping mode NanoWizard atomic force microscopy (AFM) (JPK Instruments AG, Berlin, Germany). RTESP silicon AFM probes with spring constants of 40 N/m (Veeco, Santa Barbara, CA, USA) were used for scanning in the air. The scan frequency was 1 Hz. The ambient temperature was kept at 25°C with humidity <30%. Images were processed using AFM offline data processing software.
Effects of the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 on Raji cells and YTS cells in vitro
To observe the morphological cell changes brought about by the use of the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20, Raji and YTS cells were seeded into 6-well plates at a density of 2.5×105 cells/well. Cells were cultured in an incubator at 37°C in the presence of 5% CO2. When the cells achieved exponential cell proliferation, formulations of the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 were added to the cell cultures with a final DOX concentration of 1–10 μg/mL.
At 48 hours after dosing, the cultured cells were imaged and photographed using light microscopy. The survival rate of cells was assessed using the MTT assay and was calculated using the following formula:
where A570 nm is the absorbance value. The dose–effect curves were plotted. All the experiments were performed in triplicate.
Drug targeting capability of the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 on cultured Raji cells
The intracellular targeting efficiency of the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 complex was assessed by flow cytometry. Raji or YTS cells were seeded into 6-well culture plates with a density of 2.5×105 cells/well and cultured for 24 hours at 37°C. The cells were treated with ACNP-DOX or the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 at a concentration of 10 mM DOX. After incubation for 3 hours, the cells were resuspended in PBS.
The fluorescence intensities of DOX in cells were examined by FACScan (Becton Dickinson, San Jose, CA, USA) flow cytometry (excitation at 488 nm; emission at 590 nm). In a competition assay, the cells were preincubated with 5 mg/mL anti-CD20 antibodies for 30 minutes to saturate the cell surface CD20 antigens, before ACNP-DOX or the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 were added. For a qualitative analysis of the ability of the NDDS to target the B cells, CD20-positive Raji cells or CD20-negative YTS cells were seeded into 6-well culture plates and treated with ACNP-DOX or the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 as described earlier. Following 3 hours of incubation, the drug-treated cells were washed with PBS and fixed with 4% (v/v) paraformaldehyde, followed by (blue fluorescence) cell nuclear staining with Hoechst 33258. The cells were examined by confocal laser scanning microscopy (Leica, Heidelberg, Germany).34
Data were presented as mean ± standard deviation.
Results and discussion
Particle size of the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20
As shown in Table 1, the particle size of ACNP-DOX was 140.2±19.1 nm, being almost the same as that of ACNP (138.6±28.6 nm), indicating that the loading of DOX had not changed the size of the particles significantly, because DOX was loaded into the micropores of the ACNP.
The particle size of ACNP-DOX conjugated to DSPE-PEG2000 and the anti-CD20 antibody to form the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 was 290.2±21.5 nm, larger than that of ACNP-DOX-DSPE-PEG2000 (202.9±17.3 nm) and ACNP-DOX (140.2±19.1 nm).
Morphology of the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20
TEM showed that modification of ACNP changed the morphology of the formulation (Figure 2A). ACNP and ACNP-DOX particles were irregular in shape (Figure 2A1 and A2). Because carbon particles aggregate, they could only be seen at the edge of the copper mesh. ACNP-DOX, modified with DSPE-PEG2000 had a cubic morphology with good dispersion stability, as uniformly dispersed carbon particles could be seen under TEM (Figure 2A3). ACNP-DOX conjugated with the anti-CD20 antibody formed particles that were spherical in shape, as shown in Figure 2A4.
In order to demonstrate the morphology more clearly, the samples were negatively stained. There were no projections on the stained cubic particles of ACNP-DOX-DSPE-PEG2000 (Figure 2A5). However, cilia-like projections could be seen on the surface of the stained spherical particles of the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 (Figure 2A6). Although it was not possible to determine what these cilia-like projections were, it is possible that they may represent the available anti-CD20 antibodies on the surface of the ACNP-DOX-DSPE-PEG2000 complex.
Stability of the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20
After the prepared formulations (Figure 2B1) had been placed in an ampoule at room temperature for 1 month, it was observed that the ACNPs had aggregated and settled to the bottom of the ampoule in the ACNP and ACNP-DOX groups, but no precipitates were seen at the bottom of containers in ACNP-DSPE-PEG2000, ACNP-DOX-DSPE-PEG2000, and ACNP-DOX-DSPE-PEG2000-anti-CD20 groups (Figure 2B2).
In the early preliminary experiments, it was found that the unmodified ACNP in the suspension would settle to the bottom of the ampoule in less than half an hour, whether in water or salt solution. These results demonstrated that the unmodified ACNP suspension had poor stability, and the loading of DOX did not improve the dispersion of ACNP. The structures of the DSPE-PEG2000 and DSPE-PEG2000-anti-CD20 satisfactorily improved the stability of the ACNP suspension.
Confirmation of the conjugation of the components the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20
DOX showed a characteristic UV absorbance peak at 480 nm (Figure 2C), which disappeared when DOX was adsorbed in the pores of the ACNP. The ACNP, ACNP-DOX, and ACNP-DOX-DSPE complexes had no absorbance at 200–500 nm and only ACNP-DOX-DSPE-anti-CD20 had a significant absorption peak at 254 nm.
Sodium dodecylsulfate polyacrylamide gel electrophoresis was used to determine whether antibodies were conjugated with the nanoparticles. Figure 2D shows that the first, second, third, and fourth lanes of the gel include concentrations of 2, 4, 3, and 6 μg/mL of anti-CD20 antibodies; the fifth lane includes the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20; the sixth lane shows ACNP-DOX-DSPE-PEG2000 (ACNP unconjugated from anti-CD20). The coupling efficiency of anti-CD20 antibody was found to be 20.23%±2.5%.
DL of the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20
Figure 2E shows that free DOX was found to have a strong fluorescence at 590 nm, which was not seen with other ACNP preparations using fluorescence spectrophotometry. Figure 2F shows the in vitro release profiles of DOX from ACNP-DOX, ACNP-DOX-DSPE-PEG2000 and the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20, which were investigated in pH 7.4 and 5.5 PBS at 37°C, with similar cumulative release behavior (Figure 2F). The release rates were no more than 20% in pH 7.4 PBS at 37°C during 48 hours, but at pH 5.5 they were 60% within 12 hours.
This pH triggering effect could be because, in acidic pH conditions, DOX is positively charged and water soluble, and the –COOH on the surface of ACNP could be acidified, thereby reducing the drug–ACNP interactions to allow DOX to be released from the ACNP. The ACNP modified with DSPE-PEG2000 reduced the aggregation in aqueous solution to increase the release of DOX. This pH-sensitive release of DOX may be significant because of the acidic microenvironments found in tumor tissues and cell lysosomes.36
The DL content of DOX in the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 was 20.1%±1.6%, which was less than that for the ACNP-DOX-DSPE-PEG2000 complex (29.8%±2.56%) and the ACNP-DOX complex (31.2%±2.64%), as shown in Table 1, which may be attributed to the increasing size of the complex, including the additional conjugated antibody.
The zeta potential measurements (−6.72±1.1 mV) also supported the integrity of the preparation process of the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20, as shown in Table 1.
Effects of the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 on Raji cells in vitro
The Raji cells, which are positive for cell membrane expression of CD20, grew in vitro in cohesive clusters (Figure 3A1). The YTS cells were larger than the Raji cells and were less cohesive when grown in vitro (Figure 3A2).
AFM showed the surface characteristics of both the Raji and YTS cells, and showed that the Raji cell membrane appeared to be pitted (Figure 3A3 and A4). The YTS cells were larger than the Raji cells and had a smooth surface (Figure 3A5 and A6). Figure 3A4 and A6 is a high-resolution single cell image of Raji and YTS cells, respectively.
The possible cytotoxicity of the ACNPs was studied by toxicity testing of their in vitro effects. Figure 4A shows the light microscopic morphology of Raji cells cultured in 20 μg/mL ACNP for 72 hours, with comparison of the untreated Raji cells (Figure 4A1) and the treated Raji cells (Figure 4A2). AFM showed that the surface of the Raji cells in the control group (Figure 4B1 and B2) showed no abnormalities when compared with the ACNP-treated group (Figure 4B3 and B4). Figure 4C1 shows that TEM demonstrated no differences in the ultrastructure of the nucleus and organelles between ACNP-treated and untreated cells, although ACNPs were demonstrated to enter the cell (black arrows in Figure 4C2).
The MTT assays showed that treatment with ACNP did not inhibit the growth of Raji cells even at the highest concentration (100 μg/mL) (Figure 4D), indicating that ACNP may be a potential drug delivery carrier that is without immediate cytotoxicity.
Figure 5A shows the Raji and YTS cells morphological changes resulting from the inhibitory effects of the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20, and the other formulations. Under light microscopy, control Raji (A1a) and YTS (A2a) cells grew in cohesive clusters, showing a strong proliferation activity. Compared with ACNP-DOX (Figure 5A1b and Figure 5A2b), ACNP-DOX-DSPE-PEG2000 (Figure 5A1c and Figure 5A2c) showed stronger cell inhibitory effects on CD20-positive cells (Figure 5A1) and CD20-negative cells (Figure 5A2). However, the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 treated CD20-positive cells grew in noncohesive groups and showed early cell lysis (Figure 5A1d), while the CD20-negative YTS cells continued to grow in cohesive groups (Figure 5A2d). Free DOX (Figure 5A1e and Figure 5A2e) showed the strongest cell inhibitory effects on Raji and YTS cells. Treatment with CD20 antibodies alone resulted in weak inhibitory effects on Raji and YTS cells (Figure 5A1f and Figure 5A2f).
Figure 5B shows the inhibitory effects of various formulations on CD20-positive Raji cells and CD20-negative YTS cells measured with the MTT assay. Figure 5B1 and B2 show that, among all the formulations used, free DOX had the strongest cytolytic effect on both Raji and YTS cells, indicating that DOX alone had no cell selectivity. This finding supports the nonselective chemotherapeutic toxicity of DOX seen clinically.
The inhibitory effect of the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 on Raji cells was almost the same as that of free DOX (Figure 5B1), but had a milder effect on YTS cells than that of DOX alone (Figure 5B2), indicating that anti-CD20 conjugated NDDS had a targeted cytolytic effect on CD20-positive Raji cells.
The nonantibody conjugated complexes, ACNP-DOX and ACNP-DOX-DSPE-PEG2000, had mild inhibitory effects on both Raji cells and YTS cells, which was consistent with the characteristic of ACNP as a sustained-release drug carrier. In the MTT assays, the optical absorbance was the parameter that indicated cell viability. However, because the color of ACNPs is black, the measured optical absorbance values in high doses were greater than in low doses. These findings have demonstrated that the MTT assay using optical absorbance was of less value than light microscopic imaging for assessment of cell viability resulting from treatment with these ACNPs.
Figure 6A shows the uptake of DOX, which has mild autofluorescent properties, imaged using confocal laser microscopy to evaluate cells treated with various formulations. The control Raji cells (Figure 6Aa) had no red fluorescence of DOX found in their nuclei. The Raji cells treated with ACNP-DOX (Figure 6Ab) had the weakest of red fluorescence in all the prepared complexes. The free DOX (Figure 6Ac) treated Raji cells had the strongest red fluorescence of DOX. The fluorescence concentration of DOX in the nuclei of Raji cells treated with the ACNP-DOX-DSPE (Figure 6Ad) was slightly stronger than the ACNP-DOX (Figure 6Ab), meaning that ACNP is a sustained-release drug carrier. The concentration of DOX in the nuclei of Raji cells treated with the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 (Figure 6Ae) was the greatest of all the prepared complexes and was equivalent to that of DOX treatment alone (Figure 6Ac). Pretreatment with the monoclonal anti-CD20 antibody(Figure 6Af), which blocked cell surface CD20, reduced the fluorescence of intracellular DOX. These results indicated that the targeting effect of the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 resulted from the selective improvement of intracellular DOX concentration in CD20-positive Raji cells.
In Raji cells, treatment with the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 resulted in the second highest uptake of DOX (Figure 6B1), but in YTS cells, treatment resulted in the lowest amount of DOX uptake (Figure 6B2). These results indicated that the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 had the most significant targeting effects on CD20-positive Raji cells.
Figure 6C shows the fluorescence microscopy observation of the morphology of cell apoptosis in Raji cells (Figure 6C1) and YTS cells (Figure 6C2) following treatment with various formulations of DOX (1 μg/mL) for 24 hours at 37°C. The untreated cells (Figure 6C1a and C2a) showed no observable apoptosis, displaying normal nuclear morphology. Apoptotic cell morphology, appeared in the ACNP-DOX-DSPE-PEG2000 complex (Figure 6C1b and C2b) and the Raji cells treated with the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 (Figure 6C1c). Apoptosis was not present in the YTS cells treated with the NDDS, ACNP-DOX-DSPE-PEG2000-anti-CD20 (Figure 6C2c), indicating that the antibody-conjugated nanoparticles have a selectivity for CD20-positive Raji cells. The complexes, ACNP-DOX modified with DSPE-PEG2000 showed no selectivity for CD20-positive or CD20-negative cells. Also, the complex, ACNP-DOX (Figure 6C1d and C2d) induced less early apoptosis than free DOX, indicating that ACNP is a sustained-release drug carrier. The ACNP-DSPE-PEG2000 treated cells (Figure 6C1e and C2e) showed no observable apoptosis as the control cells. These findings indicate that ACNP has low cytotoxicity, which supports the results described earlier from the MTT, AFM and microscopy studies. Apoptotic cell morphology, including nuclear chromatin condensation, nuclear condensation, the breakdown of nuclear membrane and formation of apoptotic bodies, appeared in both Raji and YTS treated with free DOX (Figure 6C1f and C2f).
In clinical practice, B-cell lymphomas may become resistant to chemotherapy agents, even with increasing doses of treatment, and chemotherapy toxicity is common and may have serious consequences. Improved drug delivery systems with reduced toxicity and targeted specifically to B cells would be important clinically. This study shows that it is possible to develop an anti-CD20 antibody-conjugated ACNP-DOX, which results in a slower intracellular DOX concentration in ACNP-DOX treated B cells than in cells treated with DOX alone. Also, when this drug delivery complex is conjugated with a monoclonal antibody to CD20, the intracellular DOX concentration in treated CD20-positive B cells is almost the same as that in the cells treated with free DOX.
Although this is a small, preliminary in vitro study, it has shown the possibility of targeting the effects of an antibody-conjugated NDDS and the benefits of using the specific antigen-antibody interaction in drug delivery. The cell targeting of the antibody-conjugated NDDS ensures that the drug concentration around the target cells is greater than that around the nontarget cells. The increased drug concentration allows more cytotoxic drug delivery to the target cells, which offsets the influences of slower drug release by the NDDS. Although these findings have been demonstrated in a controlled and preliminary in vitro system, authors believe that further studies should be conducted to determine whether this form of NDDS has the same effects in vivo using animal studies.
The findings of this in vitro study have shown that the DSPE-PEG2000 polymeric liposome is an effective nanocarrier of both a monoclonal antibody and a chemotherapy agent, and can be used to target chemotherapy to specific cells, in this case to CD20-positive B cells. Future developments in this form of targeted therapy will depend on the development of monoclonal antibodies that are specific for malignant cells, including antibodies that can distinguish between lymphoma cells and normal lymphocyte subsets.
This work was financially supported by the China Postdoctoral Science Foundation (2014M562605). The authors thank Ronggang Xi for his help with the cell culture and the preparation of sections for transmission electron microscopy.
The authors report no conflicts of interest in this work.
Sun J, Yang Q, Lu Z, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138(3):429–434.
Cheah CY, Fowler NH, Wang ML. Breakthrough therapies in B-cell non-Hodgkin lymphoma. Ann Oncol. 2016;27(5):778–787.
Judith J, Felix B, Susanne M, Hantel C, Süss R. Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo challenges and prospects. Oncotarget. 2015;6(41):43698–43711.
Shetty RK, Adams BH, Tun HW, Runyan BR, Menke DM, Broderick DF. Use of rituximab for periocular and intraocular mucosa-associated lymphoid tissue lymphoma. Ocul Immunol Inflamm. 2010;18(2):110–122.
Esmaeli B, McLaughlin P, Pro B, et al. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol. 2009;20(4):709–714.
Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res. 2002;62(4):1083–1086.
Murawski N, Zwick C, Pfreundschuh M. Unresolved issues in diffuse large B-cell lymphomas. Expert Rev Anticancer Ther. 2010;10(3): 387–402.
Piktel E, Niemirowicz K, Wątek M, Wollny T, Deptuła P, Bucki R. Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy. J Nanobiotechnology. 2016; 14(1):39.
Bertrand N, Wu J, Xu XY, Kamaly N, Farokhzad OC. Cancer Nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2–25.
Stylianopoulos T, Jain RK. Design considerations for nanotherapeutics in oncology. Nanomedicine. 2015;11(8):1893–1890.
Yu M, Zheng J. Clearance Pathways and Tumor Targeting of Imaging Nanoparticles. ACS Nano. 2015;9(7):6655–6674.
Cerqueira BB, Lasham A, Shelling AN, Al-Kassas R. Nanoparticle therapeutics: technologies and methods for overcoming cancer. Eur J Pharm Biopharm. 2015;97(Pt A):140–151.
Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136–151.
Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular permeability: Where is the missing link? J Control Release. 2012;164(3):265–275.
Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(3):53–71.
Yokota T, Saito T, Narushima Y, et al. Lympha-node staining with activated carbon CH40: a new method for axillary lymph-node dissection in breast cancer. Can J Surg. 2000;43(3):191–196.
Nakase Y, Hagiwara A, Kin S, et al. Intratumoral administration of methotrexate bound to activated carbon partieles: antitumor effectiveness against human colon carcinoma xenografts and acute toxicity in mice. J Pharmacol Exp Ther. 2004;311(1):382–387.
Hagiwara A, Torii T, Sawai K, et al. Local injection of anti-cancer drugs bound to carbon particles for early gastric cancer – a pilot study. Hepatogastroenterology. 2000;47(32):575–578.
Zhong Y, Shuzheng M, Yingge Z. Using activated carbon nanoparticles to decrease the genotoxicity and teratogenicity of anticancer therapeutic agents. J Nanosci Nanotechnol. 2010;10(12):8603–8609.
Zhao B, Sun L, Zhang W, et al. Secretion of intestinal goblet cells: a novel excretion pathway of nanoparticles. Nanomedicine. 2014;10(4):839–849.
Liu Zh, Robinson JT, Sun XM, Dai HJ. PEGylated nanographene oxide for delivery of water insoluble cancer drugs. J Am Chem Soc. 2008;130(33):10876–10877.
Sahu A, Choi WI, Lee JH, Tae G. Graphene oxide mediated delivery of methylene blue for combined photodynamic and photothermal therapy. Biomaterials. 2013;34(26):6239–6248.
Shen H, Zhang L, Liu M, Zhang Z. Biomedical applications of graphene. Theranostics. 2012;2(3):283–294.
Qu QL, Zhang YG, Sun L. Adsorption and sustained release of mitomycin C by activated carbon nano-particles. Bull Acad Mil Med Sci. 2004;28(6):551–552.
Qu QL, Zhang YG, Yang LZ, Sun L. Intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles for nude mice bearing human gastric carcinoma. Chin J Oncol. 2006;28(4):257–261.
Sun L, Zhang YG, Yang LZ. Observation of the lymph tissue-targeting property, retention in the intraperitoneal activated carbon nano-particles in mice. Bull Acad Mil Med Sci. 2005;29(4):349–351.
Yang LZ, Sun L, Zhang YG. Distribution, migration and excretion of bio-inert nano-particles in vivo. Lett Biotechnol. 2005;16(5): 525–527.
Zhang H, Sun L, Xiao E, Qu QL, Jiang S, Zhang YG. Intraperitoneal chemotherapy with mitomycin C bound to activated carbon nanoparticles using bioluminescence imaging technology. Mil Med Sci. 2011;35(4):299–303.
Yang LZ, Zhang YG. Pharmacokinetic study of intraperitoneal chemotherapy with mitomycin C absorbed to activated carbon particles in rats. J Cancer Prev Treat. 2008;15(20):1548–1551.
Mezzaroba N, Zorzet S, Secco E, et al. New potential therapeutic approach for the treatment of B-cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. Plos One. 2013;8(9):e74216.
Zhu X, Wu J, Shan W, et al. Polymeric nanoparticles a menable to simultaneous installation of exterior targeting and interior therapeutic proteins. Angew Chem Int Ed Engl. 2016;55(10):3309–3312.
Li Y, Yuan JN, Yang Q, et al. Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma. Int J Nanomed. 2014;9:5683–5700.
Yao HJ, Zhang YG, Sun L, Liu Y. The effect of hyaluronic acid functionalized carbon nanotubes loaded with salinomycin on gastric cancer stem cells. Biomaterials. 2015;35(33):9208–9223.
Yao HJ, Sun L, Liu Y, et al. Monodistearoylphosphatidylethanolamine-hyaluronic acid functionalization of single-walled carbon nanotubes for targeting intracellular drug delivery to overcome multidrug resistance of cancer cells. Carbon. 2016;96:362–376.
Roskopf CC, Braciak TA, Fenn NC, et al. Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells. Oncotarget. 2016;7(16):22579–22589.
Ying X, Wen H, Lu WL, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release. 2010;141(2):183–192.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]